- Home
- PHVS vs THM Comparison
PHVS vs THM Comparison
Compare PHVS & THM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- THM
- Stock Information
- Founded
- PHVS 2015
- THM 1978
- Country
- PHVS Switzerland
- THM Canada
- Employees
- PHVS N/A
- THM N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- THM
- Sector
- PHVS Health Care
- THM
- Exchange
- PHVS Nasdaq
- THM Nasdaq
- Market Cap
- PHVS 980.3M
- THM N/A
- IPO Year
- PHVS 2021
- THM N/A
- Fundamental
- Price
- PHVS $17.07
- THM $0.86
- Analyst Decision
- PHVS Buy
- THM
- Analyst Count
- PHVS 6
- THM 0
- Target Price
- PHVS $37.17
- THM N/A
- AVG Volume (30 Days)
- PHVS 54.0K
- THM 337.6K
- Earning Date
- PHVS 08-13-2025
- THM 08-08-2025
- Dividend Yield
- PHVS N/A
- THM N/A
- EPS Growth
- PHVS N/A
- THM N/A
- EPS
- PHVS N/A
- THM N/A
- Revenue
- PHVS N/A
- THM N/A
- Revenue This Year
- PHVS N/A
- THM N/A
- Revenue Next Year
- PHVS N/A
- THM N/A
- P/E Ratio
- PHVS N/A
- THM N/A
- Revenue Growth
- PHVS N/A
- THM N/A
- 52 Week Low
- PHVS $11.51
- THM $0.40
- 52 Week High
- PHVS $25.50
- THM $1.09
- Technical
- Relative Strength Index (RSI)
- PHVS 50.14
- THM 53.92
- Support Level
- PHVS $16.78
- THM $0.83
- Resistance Level
- PHVS $17.53
- THM $0.95
- Average True Range (ATR)
- PHVS 1.09
- THM 0.06
- MACD
- PHVS 0.00
- THM -0.01
- Stochastic Oscillator
- PHVS 29.50
- THM 40.65
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.